Recipharm signs manufacturing agreement with Alcon and acquires facility in France, adding new niche capabilities.
Recipharm AB has entered into the previously announced strategic collaboration with Alcon, a Novartis company, and today signed a long term supply agreement whereby Recipharm will manufacture a range of ophthalmic products using Blow Fill Seal technology. As part of this collaboration, Recipharm will also acquire from Alcon, Kaysersberg Pharmaceuticals,
a company whose main asset is a manufacturing facility located in Kaysersberg, France which currently supplies this product range.
Thomas Eldered, CEO Recipharm AB commented “We are looking forward to extending our relationship with Alcon and Novartis and I am very pleased that they have had the confidence in Recipharm to make this commitment of a long term manufacturing agreement and sale of Kaysersberg Pharmaceuticals. Blow Fill Seal technology is a very interesting area which we believe will grow and it therefore forms an important addition to our portfolio. The high skill levels and dedicated employees in Kaysersberg will be a welcome addition into Recipharm and we look forward to working with them to further develop and grow the business.”
Financing and payment terms
• The consideration of EUR 18 million will be paid in cash with 75% in 2015 and 25% in
• In addition, Recipharm will acquire working capital for approximately EUR 4.2 million.
• The acquisition will be financed will already available funds. No further financing will be